|
1
|
Kapranov P, Cheng J, Dike S, Nix DA,
Duttagupta R, Willingham AT, Stadler PF, Hertel J, Hackermuller J,
Hofacker IL, et al: RNA maps reveal new RNA classes and a possible
function for pervasive transcription. Science. 316:1484–1488. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dahariya S, Paddibhatla I, Kumar S,
Raghuwanshi S, Pallepati A and Gutti RK: Long non-coding RNA:
Classification, biogenesis and functions in blood cells. Mol
Immunol. 112:82–92. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Charles Richard JL and Eichhorn PJA:
Platforms for investigating LncRNA functions. SLAS Technol.
23:493–506. 2018.PubMed/NCBI
|
|
4
|
Jia B, Xie T, Qiu X, Sun X, Chen J, Huang
Z, Zheng X, Wang Z and Zhao J: Long noncoding RNA FALEC inhibits
proliferation and metastasis of tongue squamous cell carcinoma by
epigenetically silencing ECM1 through EZH2. Aging (Albany NY).
11:4990–5007. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lim LJ, Wong S, Huang F, Lim S, Chong SS,
Ooi LL, Kon OL and Lee CG: Roles and regulation of long non-coding
RNAs in hepatocellular carcinoma. Cancer Res. 79:5131–5139. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Raveh E, Matouk IJ, Gilon M and Hochberg
A: The H19 Long non-coding RNA in cancer initiation, progression
and metastasis-a proposed unifying theory. Mol Cancer. 14:1842015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yoshimura H, Matsuda Y, Yamamoto M, Kamiya
S and Ishiwata T: Expression and role of long non-coding RNA H19 in
carcinogenesis. Front Biosci (Landmark Ed). 23:614–625. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bao MH, Szeto V, Yang BB, Zhu SZ, Sun HS
and Feng ZP: Long non-coding RNAs in ischemic stroke. Cell Death
Dis. 9:2812018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zeng Y, Li TL, Zhang HB, Deng JL, Zhang R,
Sun H, Wan ZR, Liu YZ, Zhu YS and Wang G: Polymorphisms in IGF2/H19
gene locus are associated with platinum-based chemotherapeutic
response in Chinese patients with epithelial ovarian cancer.
Pharmacogenomics. 20:179–188. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ghaedi H, Zare A, Omrani MD, Doustimotlagh
AH, Meshkani R, Alipoor S and Alipoor B: Genetic variants in long
noncoding RNA H19 and MEG3 confer risk of type 2 diabetes in an
Iranian population. Gene. 675:265–271. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gomez J, Lorca R, Reguero JR, Martín M,
Morís C, Alonso B, Iglesias S, Díaz-Molina B, Avanzas P and Coto E:
Genetic variation at the long noncoding RNA H19 gene is associated
with the risk of hypertrophic cardiomyopathy. Epigenomics.
10:865–873. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tarnowski M, Tkacz M, Czerewaty M,
Poniewierska-Baran A, Grymuła K and Ratajczak MZ: 5-Azacytidine
inhibits human rhabdomyosarcoma cell growth by downregulating
insulin-like growth factor 2 expression and reactivating the H19
gene product miR-675, which negatively affects insulin-like growth
factors and insulin signaling. Int J Oncol. 46:2241–2250. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wei Y, Liu Z and Fang J: H19 functions as
a competing endogenous RNA to regulate human epidermal growth
factor receptor expression by sequestering let7c in gastric cancer.
Mol Med Rep. 17:2600–2606. 2018.PubMed/NCBI
|
|
14
|
Ma L, Tian X, Guo H, Zhang Z, Du C, Wang
F, Xie X, Gao H, Zhuang Y, Kornmann M, et al: Long noncoding RNA
H19 derived miR-675 regulates cell proliferation by down-regulating
E2F-1 in human pancreatic ductal adenocarcinoma. J Cancer.
9:389–399. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang J, Han C, Ungerleider N, Chen W,
Song K, Wang Y, Kwon H, Ma W and Wu T: A transforming growth
factor-β and H19 signaling axis in tumor-initiating hepatocytes
that regulates hepatic carcinogenesis. Hepatology. 69:1549–1563.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Han J, Han B, Wu X, Hao J, Dong X, Shen Q
and Pang H: Knockdown of lncRNA H19 restores chemo-sensitivity in
paclitaxel-resistant triple-negative breast cancer through
triggering apoptosis and regulating Akt signaling pathway. Toxicol
Appl Pharmacol. 359:55–61. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
El Hajj J, Nguyen E, Liu Q, Bouyer C,
Adriaenssens E, Hilal G and Ségal-Bendirdjian E: Telomerase
regulation by the long non-coding RNA H19 in human acute
promyelocytic leukemia cells. Mol Cancer. 17:852018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jemal A, Siegel R, Ward E, Murray T, Xu J,
Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin.
56:106–130. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lin Y, Fu F, Chen Y, Qiu W, Lin S, Yang P,
Huang M and Wang C: Genetic variants in long noncoding RNA H19
contribute to the risk of breast cancer in a southeast China Han
population. Onco Targets Ther. 10:4369–4378. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cui P, Zhao Y, Chu X, He N, Zheng H, Han
J, Song F and Chen K: SNP rs2071095 in LincRNA H19 is associated
with breast cancer risk. Breast Cancer Res Treat. 171:161–171.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lottin S, Adriaenssens E, Dupressoir T,
Berteaux N, Montpellier C, Coll J, Dugimont T and Curgy JJ:
Overexpression of an ectopic H19 gene enhances the tumorigenic
properties of breast cancer cells. Carcinogenesis. 23:1885–1895.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Berteaux N, Lottin S, Monte D, Pinte S,
Quatannens B, Coll J, Hondermarck H, Curgy JJ, Dugimont T and
Adriaenssens E: H19 mRNA-like noncoding RNA promotes breast cancer
cell proliferation through positive control by E2F1. J Biol Chem.
280:29625–29636. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou J, Yang L, Zhong T, Mueller M, Men Y,
Zhang N, Xie J, Giang K, Chung H, Sun X, et al: H19 lncRNA alters
DNA methylation genome wide by regulating S-adenosylhomocysteine
hydrolase. Nat Commun. 6:102212015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vennin C, Spruyt N, Robin YM, Chassat T,
Le Bourhis X and Adriaenssens E: The long non-coding RNA 91H
increases aggressive phenotype of breast cancer cells and
up-regulates H19/IGF2 expression through epigenetic modifications.
Cancer Lett. 385:198–206. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Collette J, Le Bourhis X and Adriaenssens
E: Regulation of human breast cancer by the long non-coding RNA
H19. Int J Mol Sci. 18(pii): E23192017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Keniry A, Oxley D, Monnier P, Kyba M,
Dandolo L, Smits G and Reik W: The H19 lincRNA is a developmental
reservoir of miR-675 that suppresses growth and Igf1r. Nat Cell
Biol. 14:659–665. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhai LL, Wang P, Zhou LY, Yin JY, Tang Q,
Zhang TJ, Wang YX, Yang DQ, Lin J and Deng ZQ: Over-expression of
miR-675 in formalin-fixed paraffin-embedded (FFPE) tissues of
breast cancer patients. Int J Clin Exp Med. 8:11195–11201.
2015.PubMed/NCBI
|
|
29
|
Cordero F, Ferrero G, Polidoro S, Fiorito
G, Campanella G, Sacerdote C, Mattiello A, Masala G, Agnoli C,
Frasca G, et al: Differentially methylated microRNAs in
prediagnostic samples of subjects who developed breast cancer in
the European Prospective Investigation into Nutrition and Cancer
(EPIC-Italy) cohort. Carcinogenesis. 36:1144–1153. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vennin C, Spruyt N, Dahmani F, Julien S,
Bertucci F, Finetti P, Chassat T, Bourette RP, Le Bourhis X and
Adriaenssens E: H19 non coding RNA-derived miR-675 enhances
tumorigenesis and metastasis of breast cancer cells by
downregulating c-Cbl and Cbl-b. Oncotarget. 6:29209–29223. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Matouk IJ, Raveh E, Abu-Lail R, Mezan S,
Gilon M, Gershtain E, Birman T, Gallula J, Schneider T, Barkali M,
et al: Oncofetal H19 RNA promotes tumor metastasis. Biochim Biophys
Acta. 1843:1414–1426. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang J, Wang X, Chen T, Jiang L and Yang
Q: Huaier extract inhibits breast cancer progression through a
lncRNA-H19/miR-675-5p pathway. Cell Physiol Biochem. 44:581–593.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tay Y, Rinn J and Pandolfi PP: The
multilayered complexity of ceRNA crosstalk and competition. Nature.
505:344–352. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Salmena L, Poliseno L, Tay Y, Kats L and
Pandolfi PP: A ceRNA hypothesis: The Rosetta Stone of a hidden RNA
language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ebert MS and Sharp PA: Emerging roles for
natural microRNA sponges. Curr Biol. 20:R858–R861. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Franco-Zorrilla JM, Valli A, Todesco M,
Mateos I, Puga MI, Rubio-Somoza I, Leyva A, Weigel D, Garcia JA and
Paz-Ares J: Target mimicry provides a new mechanism for regulation
of microRNA activity. Nat Genet. 39:1033–1037. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhou W, Ye XL, Xu J, Cao MG, Fang ZY, Li
LY, Guan GH, Liu Q, Qian YH and Xie D: The lncRNA H19 mediates
breast cancer cell plasticity during EMT and MET plasticity by
differentially sponging miR-200b/c and let-7b. Sci Signal. 10(pii):
eaak95572017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li Z, Li Y, Li Y, Ren K, Li X, Han X and
Wang J: Long non-coding RNA H19 promotes the proliferation and
invasion of breast cancer through upregulating DNMT1 expression by
sponging miR-152. J Biochem Mol Toxicol. 312017.doi:
10.1002/jbt.21933.
|
|
39
|
Li JP, Xiang Y, Fan LJ, Yao A, Li H and
Liao XH: Long noncoding RNA H19 competitively binds miR-93-5p to
regulate STAT3 expression in breast cancer. J Cell Biochem.
120:3137–3148. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Peng F, Li TT, Wang KL, Xiao GQ, Wang JH,
Zhao HD, Kang ZJ, Fan WJ, Zhu LL, Li M, et al: H19/let-7/LIN28
reciprocal negative regulatory circuit promotes breast cancer stem
cell maintenance. Cell Death Dis. 8:e25692017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Peng F, Wang JH, Fan WJ, Meng YT, Li MM,
Li TT, Cui B, Wang HF, Zhao Y, An F, et al: Glycolysis gatekeeper
PDK1 reprograms breast cancer stem cells under hypoxia. Oncogene.
37:1062–1074. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liang R, Li Y, Wang M, Tang SC, Xiao G,
Sun X, Li G, Du N, Liu D and Ren H: MiR-146a promotes the
asymmetric division and inhibits the self-renewal ability of breast
cancer stem-like cells via indirect upregulation of Let-7. Cell
Cycle. 17:1445–1456. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang M, Li Y, Xiao GD, Zheng XQ, Wang JC,
Xu CW, Qin S, Ren H, Tang SC and Sun X: H19 regulation of oestrogen
induction of symmetric division is achieved by antagonizing Let-7c
in breast cancer stem-like cells. Cell Prolif. 52:e125342019.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
De Martino M, Forzati F, Marfella M,
Pellecchia S, Arra C, Terracciano L, Fusco A and Esposito F:
HMGA1P7-pseudogene regulates H19 and Igf2 expression by a
competitive endogenous RNA mechanism. Sci Rep. 6:376222016.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu L, Liu L and Lu S: lncRNA H19 promotes
viability and epithelial-mesenchymal transition of lung
adenocarcinoma cells by targeting miR-29b-3p and modifying STAT3.
Int J Oncol. 54:929–941. 2019.PubMed/NCBI
|
|
46
|
Pan Y, Zhang Y, Liu W, Huang Y, Shen X,
Jing R, Pu J, Wang X, Ju S, Cong H and Chen H: LncRNA H19
overexpression induces bortezomib resistance in multiple myeloma by
targeting MCL-1 via miR-29b-3p. Cell Death Dis. 10:1062019.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zheng X, Zhou Y, Chen W, Chen L, Lu J, He
F, Li X and Zhao L: Ginsenoside 20(S)-Rg3 prevents PKM2-targeting
miR-324-5p from H19 sponging to antagonize the warburg effect in
ovarian cancer cells. Cell Physiol Biochem. 51:1340–1353. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sun Y, Zhu Q, Yang W, Shan Y, Yu Z, Zhang
Q and Wu H: LncRNA H19/miR-194/PFTK1 axis modulates the cell
proliferation and migration of pancreatic cancer. J Cell Biochem.
120:3874–3886. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wei J, Gan Y, Peng D, Jiang X, Kitazawa R,
Xiang Y, Dai Y, Tang Y and Yang J: Long non-coding RNA H19 promotes
TDRG1 expression and cisplatin resistance by sequestering
miRNA-106b-5p in seminoma. Cancer Med. 7:6247–6257. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Li M, Chai HF, Peng F, Meng YT, Zhang LZ,
Zhang L, Zou H, Liang QL, Li MM, Mao KG, et al: Estrogen receptor β
upregulated by lncRNA-H19 to promote cancer stem-like properties in
papillary thyroid carcinoma. Cell Death Dis. 9:11202018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wei LQ, Li L, Lu C, Liu J, Chen Y and Wu
H: Involvement of H19/miR-326 axis in hepatocellular carcinoma
development through modulating TWIST1. J Cell Physiol.
234:5153–5162. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Li CF, Li YC, Wang Y and Sun LB: The
Effect of LncRNA H19/miR-194-5p axis on the Epithelial-mesenchymal
transition of colorectal adenocarcinoma. Cell Physiol Biochem.
50:196–213. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yan L, Zhou J, Gao Y, Ghazal S, Lu L,
Bellone S, Yang Y, Liu N, Zhao X, Santin AD, et al: Regulation of
tumor cell migration and invasion by the H19/let-7 axis is
antagonized by metformin-induced DNA methylation. Oncogene.
34:3076–3084. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Barsyte-Lovejoy D, Lau SK, Boutros PC,
Khosravi F, Jurisica I, Andrulis IL, Tsao MS and Penn LZ: The c-Myc
oncogene directly induces the H19 noncoding RNA by allele-specific
binding to potentiate tumorigenesis. Cancer Res. 66:5330–5337.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Tessier CR, Doyle GA, Clark BA, Pitot HC
and Ross J: Mammary tumor induction in transgenic mice expressing
an RNA-binding protein. Cancer Res. 64:209–214. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Liu Q, Yang B, Xie X, Wei L, Liu W, Yang
W, Ge Y, Zhu Q, Zhang J, Jiang L, et al: Vigilin interacts with
CCCTC-binding factor (CTCF) and is involved in CTCF-dependent
regulation of the imprinted genes Igf2 and H19. FEBS J.
281:2713–2725. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Stedman W, Kang H, Lin S, Kissil JL,
Bartolomei MS and Lieberman PM: Cohesins localize with CTCF at the
KSHV latency control region and at cellular c-myc and H19/Igf2
insulators. EMBO J. 27:654–666. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Popkie AP, Zeidner LC, Albrecht AM,
D'Ippolito A, Eckardt S, Newsom DE, Groden J, Doble BW, Aronow B,
McLaughlin KJ, et al: Phosphatidylinositol 3-kinase (PI3K)
signaling via glycogen synthase kinase-3 (Gsk-3) regulates DNA
methylation of imprinted loci. J Biol Chem. 285:41337–41347. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zhang K, Luo Z, Zhang Y, Zhang L, Wu L,
Liu L, Yang J, Song X and Liu J: Circulating lncRNA H19 in plasma
as a novel biomarker for breast cancer. Cancer Biomark. 17:187–194.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Jiao ZY, Tian Q, Li N, Wang HB and Li KZ:
Plasma long non-coding RNAs (lncRNAs) serve as potential biomarkers
for predicting breast cancer. Eur Rev Med Pharmacol Sci.
22:1994–1999. 2018.PubMed/NCBI
|
|
61
|
Zhang Z, Weaver DL, Olsen D, DeKay J, Peng
Z, Ashikaga T and Evans MF: Long non-coding RNA chromogenic in situ
hybridisation signal pattern correlation with breast tumour
pathology. J Clin Pathol. 69:76–81. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Shima H, Kida K, Adachi S, Yamada A, Sugae
S, Narui K, Miyagi Y, Nishi M, Ryo A, Murata S, et al: Lnc RNA H19
is associated with poor prognosis in breast cancer patients and
promotes cancer stemness. Breast Cancer Res Treat. 170:507–516.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Riaz M, Berns EM, Sieuwerts AM,
Ruigrok-Ritstier K, de Weerd V, Groenewoud A, Uitterlinden AG, Look
MP, Klijn JG, Sleijfer S, et al: Correlation of breast cancer
susceptibility loci with patient characteristics, metastasis-free
survival, and mRNA expression of the nearest genes. Breast Cancer
Res Treat. 133:843–851. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Han L, Ma P, Liu SM and Zhou X:
Circulating long noncoding RNA GAS5 as a potential biomarker in
breast cancer for assessing the surgical effects. Tumour Biol.
37:6847–6854. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Si X, Zang R, Zhang E, Liu Y, Shi X, Zhang
E, Shao L, Li A, Yang N, Han X, et al: LncRNA H19 confers
chemoresistance in ERα-positive breast cancer through epigenetic
silencing of the pro-apoptotic gene BIK. Oncotarget. 7:81452–81462.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Basak P, Chatterjee S, Weger S, Bruce MC,
Murphy LC and Raouf A: Estrogen regulates luminal progenitor cell
differentiation through H19 gene expression. Endocr Relat Cancer.
22:505–517. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Basak P, Chatterjee S, Bhat V, Su A, Jin
H, Lee-Wing V, Liu Q, Hu P, Murphy LC and Raouf A: Long non-coding
RNA H19 acts as an estrogen receptor modulator that is required for
endocrine therapy resistance in ER+ breast cancer cells. Cell
Physiol Biochem. 51:1518–1532. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zhu QN, Wang G, Guo Y, Peng Y, Zhang R,
Deng JL, Li ZX and Zhu YS: LncRNA H19 is a major mediator of
doxorubicin chemoresistance in breast cancer cells through a
cullin4A-MDR1 pathway. Oncotarget. 8:91990–92003. 2017.PubMed/NCBI
|
|
69
|
Abdel Hadi M: Breast cancer in developing
countries: The shrinking age gap. Breast J. 25:795–797. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Sinaga ES, Ahmad RA, Shivalli S and
Hutajulu SH: Age at diagnosis predicted survival outcome of female
patients with breast cancer at a tertiary hospital in Yogyakarta,
Indonesia. Pan Afr Med J. 31:1632018. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Fazel A, Hasanpour-Heidari S, Salamat F,
Rajaie S, Kazeminezhad V, Naeimi-Tabiei M, Jahangirrad A, Sedaghat
S, Hosseinpoor R, Ghasemi-Kebria F, et al: Marked increase in
breast cancer incidence in young women: A 10-year study from
Northern Iran, 2004–2013. Cancer Epidemiol. 62:1015732019.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Kaminska M, Ciszewski T, Łopacka-Szatan K,
Miotla P and Staroslawska E: Breast cancer risk factors. Prz
Menopauzalny. 14:196–202. 2015.PubMed/NCBI
|
|
73
|
Tan BS, Yang MC, Singh S, Chou YC, Chen
HY, Wang MY, Wang YC and Chen RH: LncRNA NORAD is repressed by the
YAP pathway and suppresses lung and breast cancer metastasis by
sequestering S100P. Oncogene. 38:5612–5626. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Cairns J, Ingle JN, Kalari KR, Shepherd
LE, Kubo M, Goetz MP, Weinshilboum RM and Wang L: The lncRNA
MIR2052HG regulates ERα levels and aromatase inhibitor resistance
through LMTK3 by recruiting EGR1. Breast Cancer Res. 21:472019.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Zhang H, Zhang N, Liu Y, Su P, Liang Y, Li
Y, Wang X, Chen T, Song X, Sang Y, et al: Epigenetic regulation of
NAMPT by NAMPT-AS drives metastatic progression in triple-negative
breast cancer. Cancer Res. 79:3347–3359. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Chen F, Chen J, Yang L, Liu J, Zhang X,
Zhang Y, Tu Q, Yin D, Lin D, Wong PP, et al: Extracellular
vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated
macrophages regulates aerobic glycolysis of breast cancer cells.
Nat Cell Biol. 21:498–510. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Jin X, Xu XE, Jiang YZ, Liu YR, Sun W, Guo
YJ, Ren YX, Zuo WJ, Hu X, Huang SL, et al: The endogenous
retrovirus-derived long noncoding RNA TROJAN promotes
triple-negative breast cancer progression via ZMYND8 degradation.
Sci Adv. 5:eaat98202019. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Dong H, Hu J, Zou K, Ye M, Chen Y, Wu C,
Chen X and Han M: Activation of LncRNA TINCR by H3K27 acetylation
promotes Trastuzumab resistance and epithelial-mesenchymal
transition by targeting MicroRNA-125b in breast Cancer. Mol Cancer.
18:32019. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Lu G, Li Y, Ma Y, Lu J, Chen Y, Jiang Q,
Qin Q, Zhao L, Huang Q, Luo Z, et al: Long noncoding RNA LINC00511
contributes to breast cancer tumourigenesis and stemness by
inducing the miR-185-3p/E2F1/Nanog axis. J Exp Clin Cancer Res.
37:2892018. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Yu G, Zhang W, Zhu L and Xia L:
Upregulated long non-coding RNAs demonstrate promising efficacy for
breast cancer detection: A meta-analysis. Onco Targets Ther.
11:1491–1499. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Ren J, Fu J, Ma T, Yan B, Gao R, An Z and
Wang D: LncRNA H19-elevated LIN28B promotes lung cancer progression
through sequestering miR-196b. Cell Cycle. 17:1372–1380. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Huang Z, Lei W, Hu HB, Zhang H and Zhu Y:
H19 promotes non-small-cell lung cancer (NSCLC) development through
STAT3 signaling via sponging miR-17. J Cell Physiol. 233:6768–6776.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Zhang Q, Li X, Li X, Li X and Chen Z:
LncRNA H19 promotes epithelial-mesenchymal transition (EMT) by
targeting miR-484 in human lung cancer cells. J Cell Biochem.
119:4447–4457. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Wang Q, Cheng N, Li X, Pan H, Li C, Ren S,
Su C, Cai W, Zhao C, Zhang L and Zhou C: Correlation of long
non-coding RNA H19 expression with cisplatin-resistance and
clinical outcome in lung adenocarcinoma. Oncotarget. 8:2558–2567.
2017.PubMed/NCBI
|
|
85
|
Yan J, Zhang Y, She Q, Li X, Peng L, Wang
X, Liu S, Shen X, Zhang W, Dong Y, et al: Long noncoding RNA
H19/miR-675 axis promotes gastric cancer via FADD/caspase 8/caspase
3 signaling pathway. Cell Physiol Biochem. 42:2364–2376. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Ishii S, Yamashita K, Harada H, Ushiku H,
Tanaka T, Nishizawa N, Yokoi K, Washio M, Ema A, Mieno H, et al:
The H19-PEG10/IGF2BP3 axis promotes gastric cancer progression in
patients with high lymph node ratios. Oncotarget. 8:74567–74581.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Ma C, Nong K, Zhu H, Wang W, Huang X, Yuan
Z and Ai K: H19 promotes pancreatic cancer metastasis by
derepressing let-7's suppression on its target HMGA2-mediated EMT.
Tumour Biol. 35:9163–9169. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Ma H, Yuan L, Li W, Xu K and Yang L: The
LncRNA H19/miR-193a-3p axis modifies the radio-resistance and
chemotherapeutic tolerance of hepatocellular carcinoma cells by
targeting PSEN1. J Cell Biochem. 119:8325–8335. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Pope C, Mishra S, Russell J, Zhou Q and
Zhong XB: Targeting H19, an imprinted long non-coding RNA, in
hepatic functions and liver diseases. Diseases. 5:E112017.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Yang W, Redpath RE, Zhang C and Ning N:
Long non-coding RNA H19 promotes the migration and invasion of
colon cancer cells via MAPK signaling pathway. Oncol Lett.
16:3365–3372. 2018.PubMed/NCBI
|
|
91
|
Yang W, Ning N and Jin X: The lncRNA H19
promotes cell proliferation by competitively binding to miR-200a
and derepressing β-catenin expression in colorectal cancer. Biomed
Res Int. 2017:27674842017.PubMed/NCBI
|
|
92
|
Yang Q, Wang X, Tang C, Chen X and He J:
H19 promotes the migration and invasion of colon cancer by sponging
miR-138 to upregulate the expression of HMGA1. Int J Oncol.
50:1801–1809. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Chen SW, Zhu J, Ma J, Zhang JL, Zuo S,
Chen GW, Wang X, Pan YS, Liu YC and Wang PY: Overexpression of long
non-coding RNA H19 is associated with unfavorable prognosis in
patients with colorectal cancer and increased proliferation and
migration in colon cancer cells. Oncol Lett. 14:2446–2452. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Zhang L, Wang DL and Yu P: LncRNA H19
regulates the expression of its target gene HOXA10 in endometrial
carcinoma through competing with miR-612. Eur Rev Med Pharmacol
Sci. 22:4820–4827. 2018.PubMed/NCBI
|
|
95
|
Zhao L, Li Z, Chen W, Zhai W, Pan J, Pang
H and Li X: H19 promotes endometrial cancer progression by
modulating epithelial-mesenchymal transition. Oncol Lett.
13:363–369. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Ghazal S, McKinnon B, Zhou J, Mueller M,
Men Y, Yang L, Mueller M, Flannery C, Huang Y and Taylor HS: H19
lncRNA alters stromal cell growth via IGF signaling in the
endometrium of women with endometriosis. EMBO Mol Med. 7:996–1003.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Zhu Z, Xu L, Wan Y, Zhou J, Fu D, Chao H,
Bao K and Zeng T: Inhibition of E-cadherin expression by lnc-RNA
H19 to facilitate bladder cancer metastasis. Cancer Biomark.
22:275–281. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Lv M, Zhong Z, Huang M, Tian Q, Jiang R
and Chen J: lncRNA H19 regulates epithelial-mesenchymal transition
and metastasis of bladder cancer by miR-29b-3p as competing
endogenous RNA. Biochim Biophys Acta Mol Cell Res. 1864:1887–1899.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Liu C, Chen Z, Fang J, Xu A, Zhang W and
Wang Z: H19-derived miR-675 contributes to bladder cancer cell
proliferation by regulating p53 activation. Tumour Biol.
37:263–270. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Luo M, Li Z, Wang W, Zeng Y, Liu Z and Qiu
J: Upregulated H19 contributes to bladder cancer cell proliferation
by regulating ID2 expression. FEBS J. 280:1709–1716. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Ramnarine VR, Alshalalfa M, Mo F, Nabavi
N, Erho N, Takhar M, Shukin R, Brahmbhatt S, Gawronski A, Kobelev
M, et al: The long noncoding RNA landscape of neuroendocrine
prostate cancer and its clinical implications. Gigascience. Jun
1–2018.(Epub ahead of print). doi: 10.1093/gigascience/giy050.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Zhu M, Chen Q, Liu X, Sun Q, Zhao X, Deng
R, Wang Y, Huang J, Xu M, Yan J and Yu J: lncRNA H19/miR-675 axis
represses prostate cancer metastasis by targeting TGFBI. FEBS J.
281:3766–3775. 2014. View Article : Google Scholar : PubMed/NCBI
|
